Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1WVF9kdkpocGhaNHpUTzFUTVE0amszZFk1elY5UGo2a0IyZ2VMSHoyLVhsOFlaaGJ2dXYwNTdmb3J5Sjk2eXBDQU5VdUVpNVZidWxmQ3c2NnhZRXBvUEhn?oc=5" target="_blank">Multi-objective antibody design and optimization using machine learning</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
When will 2027’s Social Security COLA be announced?
Benfica tem 'roupa nova' para receber o V. Guimarães: o onze provável
Trump announces partial ceasefire in Ukraine war as Zelenskyy says deal is ‘news to me’
James McAtee: How Oliver Glasner has transformed Nottingham Forest midfielder from forgotten man to his new Adam Wharton
Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News
<a href="https://news.google.com/rss/articles/CBMiU0FVX3lxTFBpNjMwdEdMV0lLdTR6b0NQdHpMYlN2TzcxYnpWcjZuTEFKbG5NT2lINnFyZ3dEcUpoY0N4aG1Ld01pTGdKZGF5OWNjWHJMLUFDNVE0?oc=5" target="_blank">Infinimmune bags $75M for atopic dermatitis antibody duo</a>&nbsp;&nbsp;<font color="#6f6f6f">FirstWord</font>
<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxOUmhWMV9ybDNBS1FYSHU1M2o1ZmZ2UXh0RTNhaDZLTEhQRlVXSlFudU1COF9iT19fWDFreTF4TTBtSGJzMGZNSUE4WEVnN0ZKU3FWeHFrd05qMWZVNnlodDBQS3dsczVUUnRFSGJjeHZFTDhETEY5WmNQdFloMUdXeHlnZmJuSXlsNTJnbVRsc0thUQ?oc=5" target="_blank">Treatment of antibody-mediated rejection in heart transplantation: from empirical combination to multi-target precision intervention</a>&nbsp;&nbsp;<font color="#6f6f6f">Frontiers</font>
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNLXZlaVJtLWttc2pYaTNLX0RzYjg0a3dxakhUdGZlbFhCVUtVZjFOMUd3bG9hMzdYTWM2TkJUX21nUldJdFZzQ25hcHJrbUo2S3JvZ1pMWHUzOVV6OVRoY0tRenpVMVZ6dk4xMWxnUmJqR1VicVRIbFlFckYwSDlVUDRUZnhLMXFWcHVNRGt3Qlc1TVVZTEp1WlBxTnk5RmxWTkZ1bmFObnNfYXd6bUl3d2NYRnAyNU1MdTYzN0NsWE9OQWdZLWFVNkVScTQ1UQ?oc=5" target="_blank">Relapsed or Refractory Multiple Myeloma: Early-Phase Trial Investigates Novel Bispecific Antibody</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPSERlbWVLOGJtWHJ5TmRTV3JTTEJtOFl6RlR5OERaWkVZVVhXaTB1ZURDeWZfMFlNcGliU0ZsZXMtcFNwX0d0NmJ4YzhtdGt6d0lmUGR0M2lsSl9nUEt2SjdkdlkxQnFYX3R0UDZoLTR1RTJ4YTA3UGdSZE5TQ05sckZCT3pNWUd3TC1fQ0FyakpESWE5U2labFVOc2RfRXB4RUU5RDFyckdaR0FDeVVBQXY3cFBScVBuSklGLUE4SVg0QQ?oc=5" target="_blank">Self-assembling antibody drugs successfully target multiple cancer receptors</a>&nbsp;&nbsp;<font color="#6f6f6f">News-Medical</font>
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxPQ2c5Q2FwVU9FM25TcVc5R0xadUFpQmlDNExWektlTkwwWTZ4OWpiSEFiOW5oMTJXejdPWFVSYy1Fci1admxob2FvbGRBVWFlZThnbEZwSnQ4R19HNDRRcHYtWTdSZ0JaQXBYLXJ0WUx2N3d2VFZGLXJibkI3WVdfZ2QzS0Y2c01ITkE5eC1rNHZWczU5Rk83NkNRcHYtT2tsOWJTMTFBYmo5SjgxeExDT0RMcXBkOXVqTDIxZWpOZ0l4UzlVRU1CUWJFbE9XQTBEWm9fcA?oc=5" target="_blank">Infinimune CEO Dr Wyatt McDonnell on Leveraging the Human Immune System for Therapeutic Antibody Discovery</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharm International</font>
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNNkZFdURxRUFta2dMbjNRQVp5MWpwaGJ6V2ducXBTZ3hTZDY4WFpMS19WWkdKcklCelZwM05jV01Fb3pyVHFtdXUycGk1U2MzSnhlMkkyZGlNb0ZsdWJ2dzVYMHd3elZQZHkwbUh0M1gxSjRwcTFKVGtDVEhId244RWQ5OUFZN3gwa0RpM1kyelVkY1VDYkxKWU11OHVWWHpoSmhJWklFU3FISFRQMlRkU3hhQjdkUQ?oc=5" target="_blank">Multi-target screening refines ADC development for cervical cancer</a>&nbsp;&nbsp;<font color="#6f6f6f">Drug Target Review</font>
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE13TVI1WVh1T2VnRFJldS1NOUJDa1pQSGpYTlNzNS1pbnk4NkNlc2FXZWlEOVV2cnlDZ2QxUmozbkJPRDJSbGdLWUg2TW5TcHV5QlNNUlNHR3d0V1R1RVNjVm9fRzRQaVhmVmR4SU02YkphcWtBbEE?oc=5" target="_blank">Samsung Biologics Cuts Antibody Drug Development Time to 9.5 Months, Doubles Culture Productivity</a>&nbsp;&nbsp;<font color="#6f6f6f">BigGo Finance</font>
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPemVqOWpvcEE3aVRQZFNLUUhzMFR6NnV5ckxzQ3hLX1JrUVZJTHdGY0JTclNJQk9LYUZCbXNvTEd2WS0tYUhFYTI2bmUwQ29WdC1LMG9pWVNIYVdBUWhRX2JvOVMzSXd3dGl5NF9fT0VidEVGc0g0REJ0UXlBUy03YjdMNGlXQk9NTS1lN2pzc1FLSGs1bGF4b1hUTmFZeTlqazhRSVppMG5PX1M3cmJlMjdhTzQ5Q25GUDhaVnNLdHRrU0Z3eDZlRmFGTWFkWlBLeW5lUmxn?oc=5" target="_blank">Positive Signals for Bispecific and Trispecific Antibodies in Atopic Dermatitis, With Christopher Bunick, MD, PhD</a>&nbsp;&nbsp;<font color="#6f6f6f">HCPLive</font>
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPVkI4ZkhWaElzUm5EcDl6T2RTeUgtTnptNHJSZG4xQ3F6eS05NC0zZDlGdGZQdlVOYUxKdVBQUFUwOHUzRnhBNTJlR3lLLTNWSzl5c0RFVVBHVHNndnJlWGROZXNjZVFMQU5xdDM0MlYyb1E2N1hVWlRvVzFqcG9oQkh6blIwVkF6UUVGSUFGY0pmZU4zckVCUlVEMHFUNWlXVmE3X2Q3TnVsVHFtMzdVcmNlRS1fck1CQ1FRQVpTTGtVQlcxTmZabHdiUEtoMUNFTVo3VTJjX3ZOUkU0T1dGUm1FM2Z3VFJNS3ZPbg?oc=5" target="_blank">Ainnocence Shows Its Protein Foundation Model Improves Antibody-Antigen Affinity Ranking by 28% - From Sequence Alone</a>&nbsp;&nbsp;<font color="#6f6f6f">EIN News</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9md0l5T1h6ZmJLRWtlVXUwRTRQZVNabmJvTnkzcUh0QXdjLTFpR3dMeHhHU1BMSEM1T0R0NlozcEY3SFpOSkNQdlpncDNxVGIxdEhrTDVXd3RIZ0FRYnZZ?oc=5" target="_blank">FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQcjlkVnRhcXdPbzJ1MGd1eHpDOUdNMjNNd2pac1hCMUJGSWxFR1RNQzA4RDR2bXltY3BIbmozRVhxaHRyRF8xbG5rYlVrMGQ4TDU5M2sxbUw0SGQ0NHh4Y0FFSm03R2RncmpvNFp0Y3gzX2tUOGZTd0R5UEVEX1B0RWE3X2xxeDVRR1lwNERjX0ZEUHpKWDJlSk90X05KaTZuR1h1YVFCdXUxTUtRcElYSWpkMHl3N2JBUTRKOTJHZ2t5ejFrRVJHallCTDM3YjE0MDExVTNUTlR3Tm9jcnRoakE1TEEzTnVQamtzTThzMA?oc=5" target="_blank">Shanghai Unveils Inhaled Broad-Spectrum Influenza Antibody for Instant Protection</a>&nbsp;&nbsp;<font color="#6f6f6f">SHINE</font>
<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxNRnV3ZE5NNHdQdFV1S2JERGdVNTBPblRnVmp1T2RtNUhCc1ZiaTItaEthQ09FRWtlVWVjajg5RmhaRTU5THZSNnIzNnYtM3hNdUFZUVhOR1BrYmJRT0pkU25IaHgwSFRvQTZSZVppVWlTNUF6MFBLN21MMkhNd1dyVjhmc0paem15LXlFNTBvUWVCLXlnQnI5RTdDYjR2Z0tDcVhhcVVmQ1FhQ1ZJTkY4Q1NHZlV1d3E5VDNVWTdoTEg3VWFkc18xTWd6VFRhSHNtdC1FZXRLV0pPNXFrVERWMk1GNGdxWFBvT09XemlYQkV2R3NEai03aHdqdXVneG4zbllHRmltNTRMS1NzMzRuVWhCOA?oc=5" target="_blank">Prellis Biologics Enters Multi-Target Drug Discovery & Development Collaboration with Lilly to Advance Human Antibody Therapeutics</a>&nbsp;&nbsp;<font color="#6f6f6f">PR Newswire</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBYQ1E1VEVjcnp4Z2hqTFEzUlJoZGl3MndjanRSVTg0cFZUWktDRGlkdC1lX2JPaFNHSTdSVlFQbEZ5cXo4R3VHa3NPaDNuU25XeThuVERmV0s1NzU2cXg4?oc=5" target="_blank">Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQLW13dzJ0MUc1VmdUanZyLWhPbUxaN1NybzdBcUhlTzZ4U3Q5amhZcUsyZ0JTdkt6c19WTnQ4NnhpQVJRSlk1Tmh0YmpNcnNmSXFJMk1jVFlTUlQxNDhQQ3JFYzBJUk5nemdlaTNYbmd1MERkaE5sZ0FWdjFRanU5MllRVXZMdlNBT2p3bGQwN2F0blFBZ1hTQWppSk5YbkU?oc=5" target="_blank">Next-Generation Modalities Drive New Antibody Discovery</a>&nbsp;&nbsp;<font color="#6f6f6f">BioPharm International</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFB6MXhWUmxWeTBjWllEWFEyUzRDX192SGw1ajNmT2pnejRraXVlbEN5VUZRYlRYV1Qtb1VhR3BZQzVEcG5vX1d4Rk03eUltMXJiOTNjY1lqTk1FSGt1c1pv?oc=5" target="_blank">Extensive antibody search with whole spectrum black-box optimization</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE9XdWVJRG5wNndjZGpmdmxOa1duMm9nU25sN25ZazZ5ckZTc3NrUXNLTGtVMnRtREV5TThhNlNMTXZxSlNsSXcxVklGWDd5STFIM1kwc21Ya2tuOXJsbjZZ?oc=5" target="_blank">Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5xWnNldEQ0eHoycERQa2x1d0lSbFBINzhUVTY4X0lFQ2M3cHVTNUxGOUFQT0lZYmJRRzkxSkQ5ZmxUYzUxUmZpNGdBUmEyWXFIQXFPZWxjMUVuSGxjdjBz?oc=5" target="_blank">Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE41TWZCMWw0M1J6ZzZKaEhpRjVRWHZwNzc1Ykw3TVhHNUtEUkhadXJkMHRyM1ZGQ0FPV1lYeWxpd0d2c1ZKaHNpWXJ5VW1Vb1d0dmhsNkxQaF9vcHJXSmJJ?oc=5" target="_blank">Context-aware multi-property antibody predictor: a novel framework integrating text and protein language models</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE9JY2hSRVFrTk0xaUZXekRKVDFackoxS2pHeE5qRENOcWtMNHNwUDNzeWpuLU9JZ2RyOE1ubUZ3VGRCaFBVbm5kUVNlS0NMSV9U?oc=5" target="_blank">Antigen-specific Antibody Multi-modal Foundation Model for Functional Antibody Design</a>&nbsp;&nbsp;<font color="#6f6f6f">alphaXiv</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1tR3lTNkZ4UWRmMjhOVDc0RVEwV2FNeEZsOW84NUtNLVdxalgyMnlOYkVWdU9YYmNXSjhiMk5VdlhNZlRTbGhRdUxkWUpWc0gyWXpPVjZuVlJRcGZPaDlJ?oc=5" target="_blank">Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape</a>&nbsp;&nbsp;<font color="#6f6f6f">Science | AAAS</font>
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNM2o1Q1B4SWJHTnNQdmF6X2JId0lsR0tsVzV6S1dSaWN0cEkyRHMwZHdaUXdmSm82bThMRFlCSnpyRXdFS3FBWnJOYUxlM1BkV2xTVGVnMEN5cDA0V2M1dmF2VmktcnFFdWdCVjFBRFh0cnpYbFItOWhsR0pGUkVRX05tLXFiUkFCMFR4ZTBjTi1sRTd3NEFsNTRTRElxXzA5bUlWMGZkdmMxOWR5YjNfb2I0WGFLZWE3?oc=5" target="_blank">“Form Follows Function”: Rethinking Therapeutic Antibody Design</a>&nbsp;&nbsp;<font color="#6f6f6f">Technology Networks</font>
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxPcDFsb3psdGIzalJ1WTNCY01FS1J2N0xLTm9qeXk3dm9mM0lCMFU1V0FmTWloX2RRbDN3NzRQUmk2RHVVRGNydExNa0lxSE1JRElUaV8xcmtHSkNITEVMNjN5U2otUFBUMXB5NV9pUldrTlZwUnRXU1RjT0V3UURobExPa1RxZEYzZ2l3NnRrNGtSczkyUmlrYm5FVkc2MW1YRjVjVUtWbVJsVndxTG1rQ0FCZjl1OTJ5OHlhYkFMYnNMSnZzX0ptM1JtX3JKNWtVbUE?oc=5" target="_blank">Nona Biosciences and Kodiak Sciences partner to develop novel antibodies for ophthalmic diseases</a>&nbsp;&nbsp;<font color="#6f6f6f">Ophthalmology Times</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBpUjhNRnFaQmVuNHRnZWZ3RUlnbDdtMkJCbkVsZU5DSWc2bFVlb0dqanNRQ0NZYXFfNklnQUZxSFZyZGZLNi1xWEltejhHWG1zdWZPOUVCTjI5bnZscXdB?oc=5" target="_blank">Multi-target immunofluorescence by separation of antibody cross-labelling via spectral-FLIM-FRET</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1oVjhzWXZER1o2aU12eXBncnlod1NoTERhU210dVk2XzR1Y1J6ODFGaWc0RVc2UUs3ekRjQ21WQ294dEZQX3ZQNk02d1dDdG5QenFTNnI5d0thSElSX3h3?oc=5" target="_blank">Computationally restoring the potency of a clinical antibody against Omicron</a>&nbsp;&nbsp;<font color="#6f6f6f">Nature</font>
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxNMmJCMmU0SlFzR0lyR2JtT0tmZllJLS1iUERFZGs0SFF4eGRvbFhETkd0T1llcUtmUzBsUm43YVhfam9ydHBYRFF5dUtaNWtJc0tfM3dMOXZrRXJRZGdsMEVBT3N4YlVTMXA0NC1rV3IwbGd0M3RfVnBvdEZmamRhbHVSc0VKd0tuUHRSVm1BbXppNTVVc2FmN2FvVzhKOV9fYndoNlVpXzM2VlVFZ2RIRDdSYWhkTnhxbV9NRmZrTzBnNy1kbTJkOUFYZTh1dkJNTEQ3dVc3ZkVYZGZfVWwzQjFxNVg?oc=5" target="_blank">Translational safety assessment strategies for bispecific and multispecific antibodies</a>&nbsp;&nbsp;<font color="#6f6f6f">Clarivate</font>
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOUU9hZkExVWg3am1zcUptODdCNG9fcVpsZ1prWTQ3eWpIYXRtM0RzRVptcGJWTGRrazItUlRFSWZJbkE0MkhpNV9hYktJSU1YNEtQX0dWdkxfY1Y4NzdZNlNpMnlKdkxsOGktelRvcWlvVW5lWjBpVnQxOTA2ZWVsM2p6T2IwM09VVDBOcGgxVWFDOXgzZ0Y0Vkg2TEtWUQ?oc=5" target="_blank">Understanding the Use of Bispecific Antibodies in Multiple Myeloma</a>&nbsp;&nbsp;<font color="#6f6f6f">Cure Today</font>
<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFBWVnVlYmRZbHRaQkFUZnZsRDJvZ2JtaW0xUWtkdEN2X2dLdl9XcnZwOUM3MVNYZjA0dEEweklZSzlOelBNRV9zNkYyTlplNXl1STRZRkNGMlFmbU0zMjJHMy1jeHBBOTR5ZmFNQQ?oc=5" target="_blank">Israeli startup to use AI to transform antibody discovery, design</a>&nbsp;&nbsp;<font color="#6f6f6f">The Jerusalem Post</font>
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxOOHhkS1BnUXZ4QjVlWGtyaS1mblZwVXBkTTVfcnpWNzZURWVPT283X3FFcmVqYXpJdGt4d0NFa0l4UE1WYjdxcjk1U2RDeWpwWFJlbW55THZ1bExRbU5obFJfYzZBbkZwNkFyblZaSWR1RzRlR3Z0T3piTzNFN3pmSDMtMG1JRnE3RkM2TkIwVTVSVksxdm4xVjZUUTJTV1dSdnczbjgyaFJLRDBtN3lR?oc=5" target="_blank">CD38 Antibody Exposure vs. Refractoriness and MRD Negativity as Treatment Goal</a>&nbsp;&nbsp;<font color="#6f6f6f">Targeted Oncology</font>
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNWVU1bWdOM1lYRm9SdjB3Z0FtU2hKNWRGVXQ5dDlYNU40dEdrdFRIb2R6QVVIQXhJamRXSG9OMDlPUnJOckZyRU04XzcwX0dKVlBTcF9fcUlPYThRcU9uSmxGeUNONkthYzlGSkN3dy1rSE9ZWUQ2eS1IV2JLU2M1ZFo2RVVrWk5OX0ptT2ljNVhoUEk1bzVFbk11V2t0X1hmYUk1QlZVcUVaSmNvd200ZzBtMlVvM1p2cWhFM28xd0dnYnROVmhfRmozSVFJZw?oc=5" target="_blank">What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?</a>&nbsp;&nbsp;<font color="#6f6f6f">The ASCO Post</font>